Mustang Bio receives orphan designation from FDA for MB-102

Mustang Bio announced that the FDA has granted orphan drug designation to MB-102 for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare and incurable blood cancer with a median survival of less than 18 months and no standard of care.
https://thefly.com/landingPageNews.php?id=2839953